RT期刊文章SR电子T1住院病人住院治疗风险Perampanel治疗前后患者癫痫(p3.5 - 022)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP p3.5补充92 - 022签证官是15 A1爱德华Faught A1宣李A1 Jiyoon崔A1首页 Manoj Malhotra A1拉塞尔·l·Knoth年2019 UL //www.ez-admanager.com/content/92/15_supplement/p3.5 - 022. -文摘AB目的:评估住院病人住院治疗风险Perampanel启动后癫痫患者。背景:Perampanel,非竞争性AMPA谷氨酸受体拮抗剂,被批准治疗部分性癫痫的儿童和成人癫痫患者4岁及以上,以及辅助治疗主要广义tonic-clonic发作癫痫患者12岁及以上。设计/方法:交响曲健康,具有全国代表性的医学和药学数据库,被用于这项研究。患者发现如果他们填补了perampanel处方2014年7月到2016年6月期间。索引日期的日期的第一个填充药物。患者选择如果他们4岁与任何部分性癫痫(POS)(焦),或12岁或以上程度,任何POS或任何主要广义tonic-clonic癫痫(gtc),并连续观察一段这个日期之前还是之后。感兴趣的结果变量是为期一年的所有原因和epilepsy-related perampanel启动后住院病人的住院治疗的相对风险。结果:1771例患者纳入本研究。平均年龄33岁,55%是女性。预先索引时期相比,post-perampanel时期与住院病人住院的风险显著降低。一年期全因住院病人住院治疗风险比为0.76 (p < 0.05),与36.2%的风险预先索引相比,29.5%一年随访。同样,一年期epilepsy-related住院病人住院治疗风险比为0.72 (p < 0.05), 30.8%在预先索引时期,而在随访期间为23.9%。结论:癫痫患者,治疗perampanel,相对于一年期时期perampanel启动之前,与显著减少一年期全因和epilepsy-related住院病人住院治疗风险。Disclosure: Dr. Faught has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with As a KOL for Eisai inc. Dr. Li has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai Inc. Dr. Choi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Inc. Dr. Malhotra has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai Inc. Dr. Knoth has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai Inc.